Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY14 | Q15391 | 5/20 | 0.40 |
| ▸ | DHODH | Q02127 | 1/20 | 0.39 |
| ▸ | CTRC | Q99895 | 1/20 | 0.39 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.38 |
| ▸ | RXRA | P19793 | 2/20 | 0.36 |
| ▸ | STIM1 | Q13586 | 1/20 | 0.36 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.36 |
| ▸ | RXRB | P28702 | 1/20 | 0.36 |
| ▸ | FABP1 | P07148 | 1/20 | 0.36 |
| ▸ | TYMS | P04818 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.35 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2274756 | 0.86 | P2RY14 (0.42) | P2RY14DHODHCTRCNR4A1RXRA | |
| SCHEMBL3720193 | 0.86 | P2RY14 (0.42) | P2RY14DHODHCTRCNR4A1RXRA | |
| SCHEMBL2277151 | 0.79 | P2RX3 (0.59) | P2RX3P2RX2 | |
| SCHEMBL2271062 | 0.79 | CYP11B1 (0.39) | CNR2P2RX3P2RX2 | |
| SCHEMBL3720197 | 0.77 | P2RX3 (0.35) | P2RY14P2RX3P2RX2 | |
| SCHEMBL4177211 | 0.76 | P2RY14 (0.42) | P2RY14DHODHCTRCNR4A1RXRA | |
| SCHEMBL4051058 | 0.76 | P2RX3 (0.46) | P2RY14DHODHCTRCRXRARXRB | |
| SCHEMBL2278513 | 0.74 | DHODH (0.42) | P2RY14DHODHCTRCNR4A1RXRA | |
| SCHEMBL3727443 | 0.74 | DHODH (0.41) | P2RY14DHODHCTRCNR4A1RXRA | |
| SCHEMBL4173515 | 0.74 | CTRC (0.43) | P2RY14DHODHCTRCRXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150065521-A1 | TRIAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 MODULATORS | ROCHE PALO ALTO LLC (US) | 2015-03-05 | — | — | US | disclosed |
| EP-2607356-A1 | Triazole-substituted arylamide derivatives and their use as P2x3 and /or P2x2/3 purinergic receptor antagonists | F. Hoffmann-La Roche AG (CH) | 2013-06-26 | — | — | EP | disclosed |
| US-8440708-B2 | Triazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2013-05-14 | — | — | US | disclosed |
| US-20090170874-A1 | Triazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170874-A1 | Triazole-substituted arylamides as P2X3 and P2X2/3 antagonists | P2RX3, P2RX2, P2RX7 | P2RY14 15/4885DHODH 3983/4885CTRC 2408/4885 |
| US-20150065521-A1 | TRIAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 MODULATORS | P2RX3, P2RX2, P2RX7 | P2RY14 14/4885DHODH 4213/4885CTRC 2972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.